Financials Namwiwat Medical Corporation

Equities

NAM

THB663010007

Medical Equipment, Supplies & Distribution

End-of-day quote Thailand S.E. Other stock markets 06:00:00 2024-05-30 pm EDT			5-day change	1st Jan Change
4.8 ^THB	-0.83%		+3.45%	-30.94%

May. 29	Namwiwat Medical Corporation Public Company Limited Announces Establishment of Joint Venture Company with Vimut Hospital Holding Company Limited	CI
May. 14	Namwiwat Medical Corporation Public Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Valuation

Fiscal Period: December	2023	2024	2025	2026
Capitalization ¹	4,865	3,360	-	-
Enterprise Value (EV) ¹	4,865	3,360	3,360	3,360
P/E ratio	21.3 x	16 x	14.1 x	12.3 x
Yield	1.29%	2.29%	2.5%	2.92%
Capitalization / Revenue	4.36 x	2.82 x	2.57 x	2.33 x
EV / Revenue	4.36 x	2.82 x	2.57 x	2.33 x
EV / EBITDA	16.5 x	11.4 x	9.66 x	8.59 x
EV / FCF	21.3 x	-97.5 x	92.6 x	-314 x
FCF Yield	4.69%	-1.03%	1.08%	-0.32%
Price to Book	2.18 x	1.75 x	1.76 x	1.75 x
Nbr of stocks (in thousands)	700,000	700,000	-	-
Reference price ²	6.950	4.800	4.800	4.800
Announcement Date	2/27/24	-	-	-

¹THB in Million²THB

Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December	2022	2023	2024	2025	2026
Net sales ¹	-	1,115	1,190	1,309	1,440
EBITDA ¹	-	294.1	294	348	391
EBIT ¹	-	264.4	268	305	348
Operating Margin	-	23.71%	22.52%	23.3%	24.17%
Earnings before Tax (EBT) ¹	221.9	250.3	264	301	345
Net income ¹	175.7	200.7	212	241	276
Net margin	-	18%	17.82%	18.41%	19.17%
EPS ²	-	0.3267	0.3000	0.3400	0.3900
Free Cash Flow ¹	-	228.3	-34.46	36.27	-10.71
FCF margin	-	20.47%	-2.9%	2.77%	-0.74%
FCF Conversion (EBITDA)	-	77.63%	-	10.42%	-
FCF Conversion (Net income)	-	113.71%	-	15.05%	-
Dividend per Share ²	-	0.0900	0.1100	0.1200	0.1400
Announcement Date	4/4/23	2/27/24	-	-	-

¹THB in Million²THB

Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December	2023 Q4	2024 Q1
Net sales ¹	219.3	202.7
EBITDA	-	-
EBIT ¹	64.53	21.33
Operating Margin	29.43%	10.52%
Earnings before Tax (EBT) ¹	61.66	21.27
Net income ¹	50.16	13.27
Net margin	22.88%	6.55%
EPS	0.0736	-
Dividend per Share	-	-
Announcement Date	2/27/24	5/14/24

¹THB in Million

Estimates

Balance Sheet Analysis

Fiscal Period: December	2022	2023	2024	2025	2026
Net Debt	-	-	-	-	-
Net Cash position	-	-	-	-	-
Leverage (Debt/EBITDA)	-	-	-	-	-
Free Cash Flow ¹	-	228	-34.5	36.3	-10.7
ROE (net income / shareholders' equity)	-	12.7%	10.9%	12.6%	14.4%
ROA (Net income/ Total Assets)	-	9.92%	9.6%	10.8%	11.9%
Assets ¹	-	2,023	2,208	2,231	2,319
Book Value Per Share ²	-	3.190	2.750	2.730	2.750
Cash Flow per Share ²	-	0.4200	0.3400	0.4100	0.4600
Capex	-	-	-	-	-
Capex / Sales	-	-	-	-	-
Announcement Date	4/4/23	2/27/24	-	-	-

¹THB in Million²THB

Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Namwiwat Medical Corporation

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.8 THB

Average target price

6 THB

Spread / Average Target

+25.00%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
NAMWIWAT MEDICAL CORPORATION	-30.94%	91.24M
ABBOTT LABORATORIES	-7.16%	178B
BECTON, DICKINSON AND COMPANY	-4.86%	67.04B
DEXCOM, INC.	-4.28%	47.24B
CENCORA, INC.	+10.32%	44.62B
HOYA CORPORATION	+8.14%	42.5B
METTLER-TOLEDO INTERNATIONAL, INC.	+15.76%	29.99B
TERUMO CORPORATION	+15.53%	25.22B
WEST PHARMACEUTICAL SERVICES, INC.	-5.88%	24.14B
ZIMMER BIOMET HOLDINGS, INC.	-5.38%	23.69B

Other Medical Equipment, Supplies & Distribution